<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Pharmateca</journal-id><journal-title-group><journal-title xml:lang="en">Pharmateca</journal-title><trans-title-group xml:lang="ru"><trans-title>Фарматека</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2073-4034</issn><issn publication-format="electronic">2414-9128</issn><publisher><publisher-name xml:lang="en">Bionika Media</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">280213</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Allergicheskiy kon\"yunktivit</article-title><trans-title-group xml:lang="ru"><trans-title>Аллергический конъюнктивит</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Goryachkina</surname><given-names>L. A</given-names></name><name xml:lang="ru"><surname>Горячкина</surname><given-names>Л. А</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., профессор</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Terekhova</surname><given-names>E. P</given-names></name><name xml:lang="ru"><surname>Терехова</surname><given-names>Е. П</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.м.н., доцент</p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en"></institution></aff><aff><institution xml:lang="ru">РМАПО, Москва</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2013-11-10" publication-format="electronic"><day>10</day><month>11</month><year>2013</year></pub-date><volume>20</volume><issue>1s</issue><issue-title xml:lang="en">NO1s (2013)</issue-title><issue-title xml:lang="ru">№1s (2013)</issue-title><fpage>17</fpage><lpage>24</lpage><history><date date-type="received" iso-8601-date="2023-02-25"><day>25</day><month>02</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2013, Bionika Media</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2013, ООО «Бионика Медиа»</copyright-statement><copyright-year>2013</copyright-year><copyright-holder xml:lang="en">Bionika Media</copyright-holder><copyright-holder xml:lang="ru">ООО «Бионика Медиа»</copyright-holder></permissions><self-uri xlink:href="https://journals.eco-vector.com/2073-4034/article/view/280213">https://journals.eco-vector.com/2073-4034/article/view/280213</self-uri><abstract xml:lang="en"><p>Article is devoted to the topical issue of clinical allergology - diagnosis and treatment of allergic conjunctivitis (AC). The article presents the data on the prevalence of AC, and discusses the classification, clinical manifestations of the disease. Methods of diagnosis and treatment of various forms of AC are represented in detail, the features of effects of locally acting antihistamines, including olopatadine hydrochloride 0.1% (Opatanol), are discussed.</p></abstract><trans-abstract xml:lang="ru"><p>Статья посвящена актуальной проблеме клинической аллергологии - диагностике и лечению аллергических конъюнктивитов (АК). В статье освещаются вопросы распространенности АК, обсуждаются вопросы классификации, клинических проявлений заболевания. Подробно раскрываются современные методы диагностики и терапии различных форм АК, рассмотрены особенности действия антигистаминных препаратов местного действия, в т. ч. олопатадина гидрохлорида 0,1 % (Опатанола).</p></trans-abstract><kwd-group xml:lang="en"><kwd>allergic eye diseases</kwd><kwd>allergic conjunctivitis</kwd><kwd>topical antihistamines</kwd><kwd>olopatadine hydrochloride</kwd><kwd>Opatanol</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>аллергические заболевания глаз</kwd><kwd>аллергический конъюнктивит</kwd><kwd>антигистаминные местного действия</kwd><kwd>олопатадина гидрохлорид</kwd><kwd>Опатанол</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Клиническая аллергология: руководство для практикующих врачей / Под ред.Р.М. Хаитова. М., 2002. С. 191-206.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Клиническая иммунология и аллергология/ Под ред. Г. Лолора-мл., Т. Фишера, Д. Адельмана М., 2000. С. 162-72.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Курбачева О.М., Павлова К.С. Аллергический конъюнктивит: современный взгляд на актуальную проблему // Рос. аллергол. журнал 2011. № 1. С. 92-7.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Леппенен Н.Э., Пампура А.Н. Аллергический конъюнктивит у детей: от патогенеза к терапии // Рос. аллергол. журнал 2012. № 1. С. 70-4.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Майчук Д.Ю., Куренков В.В., Кашникова О.А. В кн. Актуальные вопросы воспалительных заболеваний глаз. М., 2001. С. 232-34.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Майчук Ю.Ф. Вестник офтальмологии. М.: 2000. № 5. С. 10-14.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Майчук Ю.Ф, Позднякова В.В., Якушина Л.Н. Опатанол (олопатадин гидрохлорид 0,1 %) в лечении аллергических заболеваний глаз // РМЖ2007. Т. 8. № 2. С. 63-7.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>МайчукЮ.Ф.,Ковалевская М.А,Бржеский В.В. и др. Синдром "красного глаза". Практическое руководство для врачей-офтальмологов. М., 2010. С. 82-3.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Мачарадзе Д.Ш. Лечение аллергических конъюнктивитов // Лечащий врач 2008. № 4. С. 20-2.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Патерсон Р., Грэммер Л.К., Гринберг П.А. Аллергические болезни: диагностика и лечение. Пер. с англ. / Под ред. А.Г. Чучалина, И.С. Гущина, Э.Г. Улумбекова, Р.С. Фасахова. М., 2000. С. 208-23.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Aguilar AJ, et al. Comparative study of clinical efficacy and tolerance in seasonal allergic conjunctivitis management with 0,1 % olopatadine hydrochloride versus 0,0 5% ketotifen fumarate. Acta Ophthalmologica Scandinavica 2000;78:52-5.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Artal MN, et al. A forced choice comfort study of olopatadine hydrochloride 0,1 % versus keto tifen fumarate 0,05 %o. Acta Ophthalmologica Scandinavica 2000;78:64-5.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Berdy GJ, et al. A comparison of the relative efficacy and clinical performance of olopatadine hydrochloride 0,1 % ophthalmic solution and ketotifen fumarate 0,025 % ophthalmic solution in the conjunctival antigen challenge model. Clinical Therapeutics 2002;22(7):1-8.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Berdy GJ, Stoppel JO, Epstein AB. Comparison of the clinical efficacy and tolerability of olopatadine hydrochloride 0,1 % ophthalmic solution and loteprednol etabonate 0,2 % ophthalmic suspension in the conjunctival allergen challenge model. Clin Ther 2002;24(6): 918-29.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Bielory L, Lien KW, Bigelsen S. Efficacy and tolerability of newer antihistamines in the treatment of allergic conjunctivitis. Drugs 2005;65(2):215-28.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Bielory L, Katelaris C, Lightman S, Naclerio R. Treating the Ocular Component of Allergic Rhinoconjunctivitis and Related Eye Disorders. Med Gen Med 2007;9(3):35-9.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Butrus, et al. Comparison of the Clinical Efficacy and Comfort of Olopatadine Hydrochloride 0,1 % Ophthalmic Solution and Nedocromil Sodium 2 % Ophthalmic Solution in the Human Conjunctival Allergen Challenge Model. Reprinted from Clinical Therapeutics. Excerpta Medica Inc 2000;22(12).</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Katelaris CH, Ciprandi G, Missotten L, et al. for the International Olopatadine Study Group. A comparison of the efficacy and tolerability of olopatadine hydrochloride 0,1 % ophthalmic solution and cromolyn sodium 2 % ophthalmic solution in seasonal allergic conjunctivitis. Clin Ther 2002;24 (10):1561-75.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Lanier BQ, Gross RD, Marks BB, et al. Olopatadine ophthalmic solution adjunctive to loratadine compared with loratadine alone in patients with active seasonal allergic conjunctivitis symptoms. Ann Allergy Asthma Immunol 2001;86:641-48.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Leonardi A, Zafirakis P. Efficacy and comfort of olopatadine versus ketotifen ophthalmic solutions: A double-masked, environmental study of patient preference. Curr Med Res Opin 2004;20(8):1167-73.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Mantelli F, Santos MS, Petitti T, et al. Systematic review and meta-analysis of randomised clinical trials on topical treatments for vernal keratoconjunctivitis. Br J Ophthalmol 2007;91(12): 1656-61.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Ono SJ, Abelson MB. Allergic conjunctivitis: update on pathophysiology and prospects for future treatment. J Allergy Clin Immunol 2005;115:118-22.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Rosenwasser LJ, O'Brien T, Weyne J. Mast cell stabilization and antihistamine effects of olopatadine ophthalmic solution: a review of preclinical and clinical research. Curr Med Res Opin 2005;21(9):1377-87.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Spangler DL, Bensch G, Berdy GJ. Evaluation of the efficacy of olopatadine hydrochloride 0,1 % ophthalmic solution and azelastine hydrochloride 0,05 % ophthalmic solution in the conjunctival allergen challenge model. Clinical Therapeutics 2001;23:1272-80.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Wuthrich B, Brignoli R, Canevascini M, et al. Epidemiological survey in hay fever patients: symptom prevalence and severity and influence on patient management. Schweiz Med Wochenschr 1998;128: 139-43.</mixed-citation></ref></ref-list></back></article>
